Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Empagliflozin for Obesity

The study will assign participants to take either the medication, empagliflozin or a dummy treatment (placebo) for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

Official registry: https://clinicaltrials.gov/study/NCT06745063 · VA Office of Research and Development · enrollment listed as 50

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Empagliflozin, or Placebo. The registry lists allocation as randomized. The study will assign participants to take either the medication, empagliflozin or a dummy treatment (placebo) for 12 weeks.

They plan to enroll about 50 people at Columbia. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Interventions: Empagliflozin, Placebo

Primary outcome (registry wording): Carotid-femoral Pulse Wave Velocity (cfPWV)

Who it is for (from inclusion criteria)

  • Ages 30 Years to 60 Years
  • Body mass index (body-mass index (BMI)) 30-45 kilograms per square meter (kg/m2)
  • 30-60 years of age at randomization
  • Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030), or presence of Stage I hypertension or higher (PMID: 30354655), or current use of antihypertensive agents

Public study contact (from the registry)

Jaume Padilla Parellada, PhD

(573) 814-6552

jaume.padillaparellada@va.gov

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

FAQ about this NCT record

Is NCT06745063 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06745063?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06745063?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary